CoChat

Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy

Ribot, Cécile, Soler, Cédric, Chartier, Aymeric, Al Hayek, Sandy, Naït-Saïdi, Rima, Barbezier, Nicolas, Coux, Olivier, Simonelig, Martine · 2022 · PLOS Genetics
Cited by 37

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset disorder characterized by progressive weakness and degeneration of specific muscles. OPMD is due to extension of a polyalanine tract in poly(A) binding protein nuclear 1 (PABPN1). Aggregation of the mutant protein in muscle nuclei is a hallmark of the disease. Previous transcriptomic analyses revealed the consistent deregulation of the ubiquitin-proteasome system (UPS) in OPMD animal models and patients, suggesting a role of this deregulation in OPMD pathogenesis. Subsequent studies proposed that UPS contribution to OPMD involved PABPN1 aggregation. Here, we use a Drosophila model of OPMD to address the functional importance of UPS deregulation in OPMD. Through genome-wide and targeted genetic screens we identify a large number of UPS components that are involved in OPMD. Half dosage of UPS genes reduces OPMD muscle defects suggesting a pathological increase of UPS activity in the disease. Quantification of proteasome activity confirms stronger activity in OPMD muscles, associated with degradation of myofibrillar proteins. Importantly, improvement of muscle structure and function in the presence of UPS mutants does not correlate with the levels of PABPN1 aggregation, but is linked to decreased degradation of muscle proteins. Oral treatment with the proteasome inhibitor MG132 is beneficial to the OPMD Drosophila model, improving muscle function although PABPN1 aggregation is enhanced. This functional study reveals the importance of increased UPS activity that underlies muscle atrophy in OPMD. It also provides a proof-of-concept that inhibitors of proteasome activity might be an attractive pharmacological approach for OPMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1010015

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 73

  1. B Boland, 2018, Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing, Nat Rev Drug Discov, 17, 660, 10.1038/nrd.2018.109 · DOI · Paper page
  2. A Abu-Baker, 2007, Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies, Biochim Biophys Acta, 1772, 173, 10.1016/j.bbadis.2006.10.003 · DOI
  3. B. Brais, 2009, Oculopharyngeal muscular dystrophy: a polyalanine myopathy, Curr Neurol Neurosci Rep, 9, 76, 10.1007/s11910-009-0012-y · DOI
  4. B Brais, 1998, Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy, Nature Genetics, 18, 164, 10.1038/ng0298-164 · DOI · Paper page
  5. L Jouan, 2014, An 18 alanine repeat in a severe form of oculopharyngeal muscular dystrophy, Can J Neurol Sci, 41, 508, 10.1017/S0317167100018588 · DOI · Paper page
  6. P Richard, 2015, PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling., J Neuromuscul Dis, 2, 175, 10.3233/JND-140060 · DOI · Paper page
  7. FM Tome, 1980, Nuclear inclusions in oculopharyngeal dystrophy, Acta Neuropathol (Berl)., 49, 85, 10.1007/BF00692226 · DOI
  8. B Benoit, 2005, An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila., Dev Cell, 9, 511, 10.1016/j.devcel.2005.09.002 · DOI
  9. B Benoit, 1999, The Drosophila poly(A)-binding protein II is ubiquitous throughout Drosophila development and has the same function in mRNA polyadenylation as its bovine homolog in vitro., Nucleic Acids Res, 27, 3771, 10.1093/nar/27.19.3771 · doi:10.1093/nar/27.19.3771
  10. Y Kerwitz, 2003, Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA., The EMBO journal, 22, 3705, 10.1093/emboj/cdg347 · DOI
  11. U Kuhn, 2009, Poly(A) tail length is controlled by the nuclear poly(A)-binding protein regulating the interaction between poly(A) polymerase and the cleavage and polyadenylation specificity factor., The Journal of biological chemistry, 284, 22803, 10.1074/jbc.M109.018226 · DOI · Paper page
  12. E. Wahle, 1991, A novel poly(A)-Binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation, Cell, 66, 759, 10.1016/0092-8674(91)90119-J · DOI · Paper page
  13. M Jenal, 2012, The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites, Cell, 149, 538, 10.1016/j.cell.2012.03.022 · DOI · Paper page
  14. N Meola, 2017, Targeting the nuclear RNA exosome: Poly(A) binding proteins enter the stage., RNA Biol, 14, 820, 10.1080/15476286.2017.1312227 · DOI
  15. YB Beaulieu, 2012, Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1., PLoS Genet, 8, e1003078, 10.1371/journal.pgen.1003078 · DOI · Paper page
  16. SM Bresson, 2013, The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay, PLoS Genet, 9, e1003893, 10.1371/journal.pgen.1003893 · DOI · Paper page
  17. DH Moon, 2015, Poly(A)-specific ribonuclease (PARN) mediates 3’-end maturation of the telomerase RNA component., Nat Genet, 47, 1482, 10.1038/ng.3423 · DOI · Paper page
  18. D Nguyen, 2015, A Polyadenylation-Dependent 3’ End Maturation Pathway Is Required for the Synthesis of the Human Telomerase RNA., Cell Rep, 13, 2244, 10.1016/j.celrep.2015.11.003 · DOI · Paper page
  19. E de Klerk, 2012, Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation., Nucleic Acids Res, 40, 9089, 10.1093/nar/gks655 · DOI · Paper page
  20. A Chartier, 2015, Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis., PLoS GenetPubMed Central PMCID, 11, e1005092, 10.1371/journal.pgen.1005092 · DOI
  21. KE Vest, 2017, Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology., Hum Mol Genet, 26, 3235, 10.1093/hmg/ddx206 · DOI · Paper page
  22. A Calado, 2000, Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein II aggregates which sequester poly(A) RNA., Hum Mol Genet, 9, 2321, 10.1093/oxfordjournals.hmg.a018924 · DOI · Paper page
  23. LP Corbeil-Girard, 2005, PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions, Neurobiol Dis, 18, 551, 10.1016/j.nbd.2004.10.019 · DOI
  24. X Fan, 2003, HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy, Can J Neurol Sci, 30, 244, 10.1017/S0317167100002675 · DOI
  25. P Klein, 2016, Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing., Nucleic Acids Res, 44, 10929, 10.1093/nar/gkw703 · DOI · Paper page
  26. SY Anvar, 2013, A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging., Aging (Albany NY).PubMed Central PMCID, 5, 412
  27. N Barbezier, 2011, Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy, EMBO Mol Med, 3, 35, 10.1002/emmm.201000109 · DOI
  28. A Chartier, 2009, Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo, Hum Mol Genet, 18, 1849, 10.1093/hmg/ddp101 · DOI
  29. A Chartier, 2013, Animal models in therapeutic drug discovery for oculopharyngeal muscular dystrophy., Drug Discov Today Technol, 10, e103, 10.1016/j.ddtec.2012.07.002 · DOI
  30. JE Davies, 2005, Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice, Nat Med, 11, 672, 10.1038/nm1242 · DOI · Paper page
  31. V Raz, 2014, A Novel Feed-Forward Loop between ARIH2 E3-Ligase and PABPN1 Regulates Aging-Associated Muscle Degeneration, Am J Pathol, 184, 1119, 10.1016/j.ajpath.2013.12.011 · DOI · Paper page
  32. V Raz, 2011, Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein, Am J Pathol, 179, 1988, 10.1016/j.ajpath.2011.06.044 · DOI · Paper page
  33. SY Anvar, 2011, Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients, Skelet Muscle, 1, 15, 10.1186/2044-5040-1-15 · DOI
  34. D Finley, 2009, Recognition and processing of ubiquitin-protein conjugates by the proteasome., Annu Rev Biochem, 78, 477, 10.1146/annurev.biochem.78.081507.101607 · DOI · Paper page
  35. J Bilen, 2007, Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila., PLoS Genet, 3, 1950, 10.1371/journal.pgen.0030177 · DOI · Paper page
  36. A Chartier, 2006, A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1, Embo J, 25, 2253, 10.1038/sj.emboj.7601117 · DOI · Paper page
  37. AH Brand, 1993, Targeted gene expression as a means of altering cell fates and generating dominant phenotypes, Development, 118, 401, 10.1242/dev.118.2.401 · DOI · Paper page
  38. S Aerts, 2009, Integrating computational biology and forward genetics, Drosophila. PLoS Genet, 5, e1000351, 10.1371/journal.pgen.1000351 · DOI
  39. D Thevenon, 2020, A Nucleolar Isoform of the Drosophila Ubiquitin Specific Protease dUSP36 Regulates MYC-Dependent Cell Growth, Front Cell Dev Biol, 8, 506, 10.3389/fcell.2020.00506 · DOI
  40. L Burri, 2000, Identification and characterization of a mammalian protein interacting with 20S proteasome precursors, Proc Natl Acad Sci U S A, 97, 10348, 10.1073/pnas.190268597 · DOI · Paper page
  41. TA Griffin, 2000, Identification of proteassemblin, a mammalian homologue of the yeast protein, Ump1p, that is required for normal proteasome assembly, Mol Cell Biol Res Commun, 3, 212, 10.1006/mcbr.2000.0213 · DOI
  42. PC Ramos, 1998, Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly, Cell, 92, 489, 10.1016/S0092-8674(00)80942-3 · DOI · Paper page
  43. E Witt, 2000, Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes., Journal of molecular biology, 301, 1, 10.1006/jmbi.2000.3959 · DOI
  44. M Carrasco-Rando, 2008, Mind bomb 2, a founder myoblast-specific protein, regulates myoblast fusion and muscle stability, Development, 135, 849, 10.1242/dev.015529 · DOI
  45. K Domsch, 2017, Identification of the essential protein domains for Mib2 function during the development of the Drosophila larval musculature and adult flight muscles, PLoS One, 12, e0173733, 10.1371/journal.pone.0173733 · doi:10.1371/journal.pone.0173733
  46. F Schnorrer, 2010, Systematic genetic analysis of muscle morphogenesis and function in Drosophila, Nature, 464, 287, 10.1038/nature08799 · DOI · Paper page
  47. A Chandra, 2010, Synthetic lethality of rpn11-1 rpn10Delta is linked to altered proteasome assembly and activity, Curr Genet, 56, 543, 10.1007/s00294-010-0321-3 · DOI
  48. MH Glickman, 1998, A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3, Cell, 94, 615, 10.1016/S0092-8674(00)81603-7 · DOI · Paper page
  49. Q Huang, 2013, Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 subunit upon mitochondrial dysfunction in neurons, J Biol Chem, 288, 12161, 10.1074/jbc.M113.464552 · DOI
  50. ER Greene, 2020, Understanding the 26S proteasome molecular machine from a structural and conformational dynamics perspective, Curr Opin Struct Biol, 61, 33, 10.1016/j.sbi.2019.10.004 · DOI
  51. P Low, 2013, Impaired proteasomal degradation enhances autophagy via hypoxia signaling in Drosophila, BMC Cell Biol, 14, 29, 10.1186/1471-2121-14-29 · DOI · Paper page
  52. JP Tavanez, 2005, In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1., Rna, 11, 752, 10.1261/rna.7217105 · DOI
  53. DM Smith, 2018, Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?, J Exp Neurosci, 12, 1179069518794675, 10.1177/1179069518794675 · DOI
  54. TA Thibaudeau, 2018, A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers., Nat CommunPubMed Central PMCID, 9, 1097
  55. D Peris-Moreno, 2020, MuRF1/TRIM63, Master Regulator of Muscle Mass., Int J Mol Sci, 21, 10.3390/ijms21186663 · DOI
  56. R Piccirillo, 2014, Mechanisms of muscle growth and atrophy in mammals and Drosophila, Dev Dyn, 243, 201, 10.1002/dvdy.24036 · DOI · Paper page
  57. C Trollet, 2010, Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres, Human molecular genetics, 19, 2191, 10.1093/hmg/ddq098 · DOI
  58. T Gidaro, 2013, Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients, J Neuropathol Exp Neurol, 72, 234, 10.1097/NEN.0b013e3182854c07 · DOI
  59. A Vignaud, 2010, Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway, Neuromuscul Disord, 20, 319, 10.1016/j.nmd.2010.03.006 · DOI
  60. M Riaz, 2016, PABPN1-Dependent mRNA Processing Induces Muscle Wasting., PLoS Genet., 12, e1006031, 10.1371/journal.pgen.1006031 · DOI
  61. S Koizumi, 2018, Transcriptional regulation of the 26S proteasome by Nrf1, Proc Jpn Acad Ser B Phys Biol Sci, 94, 325, 10.2183/pjab.94.021 · DOI
  62. MK Kwak, 2003, Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway, Mol Cell Biol, 23, 8786, 10.1128/MCB.23.23.8786-8794.2003 · DOI · Paper page
  63. KB Grimberg, 2011, Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome, Mol Cell Biol, 31, 897, 10.1128/MCB.00799-10 · DOI · Paper page
  64. EN Tsakiri, 2013, Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging, Aging Cell, 12, 802, 10.1111/acel.12111 · DOI · Paper page
  65. K Chaplot, 2019, SOD1 activity threshold and TOR signalling modulate VAP(P58S) aggregation via reactive oxygen species-induced proteasomal degradation in a Drosophila model of amyotrophic lateral sclerosis., Dis Model Mech, 12
  66. P Harish, 2019, Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)., J Cachexia Sarcopenia Muscle, 10, 1016, 10.1002/jcsm.12438 · DOI
  67. G Lavergne, 2017, Characterization of Drosophila Muscle Stem Cell-Like Adult Muscle Precursors., Methods Mol Biol, 1556, 103, 10.1007/978-1-4939-6771-1_5 · DOI
  68. M Weitkunat, 2014, A guide to study Drosophila muscle biology, Methods, 68, 2, 10.1016/j.ymeth.2014.02.037 · DOI
  69. C Polge, 2018, UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment., Cells, 7, 214, 10.3390/cells7110214 · DOI
  70. S Krause, 1994, Immunodetection of poly(A) binbing protein II in the cell nucleus., Exp Cell Res, 214, 75, 10.1006/excr.1994.1235 · DOI · Paper page
  71. S Antic, 2015, General and MicroRNA-Mediated mRNA Degradation Occurs on Ribosome Complexes in Drosophila Cells., Mol Cell Biol, 35, 2309, 10.1128/MCB.01346-14 · DOI · Paper page
  72. A Tonoki, 2009, Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process, Mol Cell Biol, 29, 1095, 10.1128/MCB.01227-08 · DOI · Paper page
  73. C Naujokat, 2007, Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition., Biochim Biophys Acta, 1773, 1389, 10.1016/j.bbamcr.2007.05.007 · DOI

Cited by

See all 37

Metadata

Authors
Ribot, C., Soler, C., Chartier, A., Al Hayek, S., Naït-Saïdi, R., Barbezier, N., Coux, O., & Simonelig, M.
Venue
PLOS Genetics
Published
2022-01-13
Volume
18
Issue
1
Pages
e1010015
ISSN
1553-7404
Cited by
37
References
8
Language
en
Funders
  • Université de Montpellier (UMR9002)
  • AFM-Téléthon (17110)
  • Fondation pour la Recherche Médicale (Equipe FRM 2013 DEQ20130326534)
  • Agence Nationale de la Recherche (ANR-09-GENO-025-01, ANR-17-CE12-0011-01)
  • ISITE CAP2025 (Challenge 3)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.